{"groups":[{"description":"Non-cryopreserved LN-144 (Gen 1 infusion product) (Closed)\n\nA tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepletion, patients are infused with lifileucel followed by IL-2.","id":"FG000","title":"Cohort 1"},{"description":"Cryopreserved lifileucel (LN-144) (Gen 2 infusion product) (Closed)\n\nLifileucel: A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepletion, patients are infused with lifileucel followed by IL-2.","id":"FG001","title":"Cohort 2"},{"description":"Retreatment cohort: patients from Cohort 1, Cohort 2 or Cohort 4 may rescreen for a second TIL regimen therapy if they meet all Inclusion and Exclusion Criteria (except exclusion criterion b) (Closed)\n\nLifileucel: A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepletion, patients are infused with lifileucel followed by IL-2.","id":"FG002","title":"Cohort 3"},{"description":"Cryopreserved lifileucel (LN-144) (Gen 2 infusion product) (Closed)\n\nLifileucel: A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepletion, patients are infused with lifileucel followed by IL-2.","id":"FG003","title":"Cohort 4"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"16"},{"groupId":"FG001","numSubjects":"49"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"71"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"3"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}],"type":"Other"},{"reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"11"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"22"}],"type":"Did not receive TIL"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"31"},{"groupId":"FG001","numSubjects":"78"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"111"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"23"},{"groupId":"FG001","numSubjects":"67"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"89"}],"type":"Patients Infused With TIL"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"14"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"14"}],"comment":"Completed refers to the number of patients who have received TIL and completed the study","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"31"},{"groupId":"FG001","numSubjects":"64"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"97"}],"type":"NOT COMPLETED"}],"title":"Initial"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"11"},{"groupId":"FG003","numSubjects":"0"}],"type":"Death"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"comment":"Cohort 3 patients had progressed following initial treatment in Cohorts 1, 2, 4 and then were retreated with a second TIL regimen. Data are captured in the retreatment period for Cohort 3","groupId":"FG001","numSubjects":"0"},{"comment":"Cohort 3 patients had progressed following initial treatment in Cohorts 1, 2, 4 and then were retreated with a second TIL regimen. Data are captured in the retreatment period for Cohort 3","groupId":"FG002","numSubjects":"12"},{"comment":"Cohort 3 patients had progressed following initial treatment in Cohorts 1, 2, 4 and then were retreated with a second TIL regimen. Data are captured in the retreatment period for Cohort 3","groupId":"FG003","numSubjects":"0"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"11"},{"groupId":"FG003","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Retreatment"}],"preAssignmentDetails":"Cohorts 1, 2, 4 refers to the initial treatment. Cohort 3 patients had progressed following the initial treatment and then were retreated with a second TIL regimen. Data are captured in the retreatment period for Cohort 3."}